Business Wire

TX-WEA

27.10.2021 10:34:07 CEST | Business Wire | Press release

Share
Women’s Entrepreneurship Accelerator Announces Partnership With Commonwealth to Drive Change for Women Entrepreneurs in 54 Countries

The Women’s Entrepreneurship Accelerator (WEA), a strategic multi-partnership convening five UN agencies and Mary Kay Inc., is today joining forces with the Commonwealth Businesswomen’s Network (CBWN) to empower and support underserved women entrepreneurs across the 54 countries of the Commonwealth.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005291/en/

WEA is designed to maximize the development impact of women entrepreneurship in achieving the Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs that fosters growth, sustainability, and resilience. In June 2021, WEA joined the Generation Equality Forum in Paris and committed to empower five million women around the world by 2030 to accelerate progress for gender equality.

WEA recently announced the launch of a series of impactful initiatives and knowledge products, all shaped through a gender lens, as the joint outcome of the collaboration between the International Labour Organization (ILO), the International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP) and UN Women with the strategic support and funding of Mary Kay. WEA’s impact work includes digital capacity building tools and training; entrepreneurship research; and gender-responsive procurement (GRP) advocacy and training.

CBWN works with women in business by connecting governments and the private sector to encourage, enable and embed women’s economic empowerment and women in leadership. Originating in May 2021, the Commonwealth Women’s Entrepreneurship Accelerator (CWEA) is a strategic multi-stakeholder partnership from the CBWN, the Global Entrepreneurship Network UK (GEN UK) and Oxentia. It is a direct response to three developments: the agreement by all Commonwealth Heads of Government in London in 2018 “to work towards an increase in the number and enhancement of the success rate of women-owned businesses, break down gender barriers in all sectors, and increase opportunities for women to trade internationally”; the recognition by the G20 in 2020 that “there is a missed opportunity – to tackle the gap that needs immediate action, which is the representation of women in emerging fields”; and the UN Global Acceleration Plan to advance gender equality by 2026 and its Action Coalitions on Economic Justice and Rights and Technology and Innovation launched in 2021.

The new partnership with CBWN in support of CWEA further solidifies WEA’s geographic scope of action across the 54 Commonwealth diverse country members in Africa, Asia, the Americas, Europe, and the Pacific, with 32 countries classified as “small states.” Small states are especially vulnerable to climate change and developmental challenges including gender inequalities.

Beyond scaling WEA and CBWN’s foundational areas of work, the partnership will also significantly focus on policy and advocacy to advance systemic change engaging Commonwealth member states and leveraging its networks of organizations and key stakeholders in support of women in business or aspiring women entrepreneurs in and across the Commonwealth.

“We know that multi-stakeholder partnerships and collective engagement is crucial to drive the change that women entrepreneurs need across sectors around the world,” said Deborah Gibbins, Chief Operating Officer of Mary Kay Inc. “WEA is thrilled to join forces with the Commonwealth Businesswomen’s Network and the Commonwealth Women’s Entrepreneurship Accelerator. Our collaboration will focus on augmenting, amplifying and accelerating impact. We’re more powerful together, and I look forward to our collective action journey in support of the SDGs.”

“The Commonwealth Businesswomen’s Network is delighted to partner with the United Nations Women’s Entrepreneurship Accelerator in this landmark initiative so we can unlock and unleash the power and potential for more women of diverse backgrounds,” said Freda Miriklis, Chair, Commonwealth Businesswomen’s Network. “Through this partnership, we’ll be able to more quickly harness our collective assets - for women, their communities and every girl that can and will be inspired by their stories.”

To learn more about the Women’s Entrepreneurship Accelerator, visit we-accelerate.com .

About the Women’s Entrepreneurship Accelerator

The Women’s Entrepreneurship Accelerator (WEA) is a multi-partnership initiative on women’s entrepreneurship convening 5 UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP), UN Women and Mary Kay Inc. to empower 5 million women entrepreneurs by 2030.

The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.

Learn more at we-accelerate . Follow us: Twitter (@We_Accelerator ), Instagram (@we_accelerator ), Facebook (@womensentrepreneurshipaccelerator ), LinkedIn (@womensentrepreneurshipaccelerator )

About the Commonwealth Businesswomen’s Network

The Commonwealth Businesswomen’s Network (CBWN) works with women in business by connecting Governments and the private sector to encourage, enable and embed women’s economic empowerment. This is achieved through delivering activities, initiatives, products, and services focused on trade, talent, and training. It is the only accredited organisation focused on women’s economic empowerment and directly recognized by 54 governments across six continents. Learn more at www.cbwn.org

About the Commonwealth Women’s Entrepreneurship Accelerator

The Commonwealth Women’s Entrepreneurship Accelerator is a strategic multi stakeholder partnership on women’s entrepreneurship established as an outcome of the inaugural Commonwealth Women’s Entrepreneurship Summit (CWES) in May 2021, the first global event to focus on women in emerging tech sectors. CWES was convened by the Commonwealth Businesswomen’s Network; the Global Entrepreneurship Network; the UK Government (Women in Innovation Network, a programme of Innovation UK); and Africa’s largest network of women entrepreneurs (AWEP: African Women’s Entrepreneurship Program). The Commonwealth Women’s Entrepreneurship Accelerator is a partnership between the Commonwealth Businesswomen’s Network, Global Entrepreneurship Network-UK and Oxentia. Learn more at www.thecwea.org

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements, and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at marykayglobal.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye